Last $152.23 USD
Change Today -1.46 / -0.95%
Volume 1.8M
ILMN On Other Exchanges
As of 12:15 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILMN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - $183.30
52 Week Low
04/24/13 - $61.79
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ILLUMINA INC (ILMN)

illumina inc (ILMN) Details

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology are designed to meet the various demands of a range of sequencing applications; and array platforms consist of HiScan and iScan systems that are array scanners, which support the imaging of array-based genetic analysis products. It also offers various sample preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping and whole genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,000 Employees
Last Reported Date: 02/18/14
Founded in 1998

illumina inc (ILMN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.1M
President and Director
Total Annual Compensation: $153.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $447.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.1K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $449.6K
Compensation as of Fiscal Year 2013.

illumina inc (ILMN) Key Developments

Illumina Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 30, 2014; Increases Earnings Guidance for 2014

Illumina Inc. reported unaudited consolidated earnings results for the first quarter ended March 30, 2014. For the quarter, revenue was $421 million compared to $331 million in the first quarter of 2013. GAAP net income was $60 million, or $0.40 per diluted share, compared to net loss of $23 million, or $0.18 per diluted share, for the first quarter of 2013. Non-GAAP net income was $80 million, or $0.53 per diluted share, compared to $63 million, or $0.46 per diluted share, for the first quarter of 2013. Income from operations was $92,096,000 compared to loss from operations of $45,147,000 a year ago. Net cash provided by operating activities was $37,087,000 compared to $87,840,000 a year ago. Free cash flow was $18,075,000 compared to $66,399,000 a year ago. Purchases of property and equipment were $19,012,000 compared to $21,441,000 a year ago. Revenue growth was 27% year-over-year as a result of positive underlying trends across all geographies and a universally positive reaction to new sequencing systems. First quarter total sequencing revenue grew 36% year-over-year, driven by impressive demand for consumables, new and existing instruments and services. Cash flow from operations was lower than previous quarters due to changes in working capital and the impact of tax benefits from stock-based compensation. Excluding the impact of the tax benefit outflow, which is mirrored as an inflow and cash from financing, cash flow from operations would have been approximately $88 million. Given strong first quarter results and the strength in demand for HiSeq X Ten, the company has updated guidance for 2014. The company now projects revenue growth of 21% to 23%, an increase from the previous guidance of 15% to 17% growth; and non-GAAP diluted EPS of $2.10 to $2.15, higher than previous guidance of $2 to $2.06. This projection includes shipping materially higher number of HiSeq X Ten than the 5 included in the January guidance. Additional modeling considerations include full year weighted average non-GAAP diluted shares outstanding of 150 million, which assumes a stock price of $140; and a full year pro forma tax rate of 29.5%, which includes the 2014 federal R&D tax credit as yet to be enacted. If the tax credit and other tax extenders are not passed, tax rate would increase by approximately 200 basis points.

Illumina Inc., Q1 2014 Earnings Call, Apr 22, 2014

Illumina Inc., Q1 2014 Earnings Call, Apr 22, 2014

Illumina Inc. to Report Q1, 2014 Results on Apr 22, 2014

Illumina Inc. announced that they will report Q1, 2014 results at 5:00 PM, Eastern Standard Time on Apr 22, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN:US $152.23 USD -1.46

ILMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $55.32 USD +0.31
Avago Technologies Ltd $64.29 USD -0.31
PerkinElmer Inc $44.35 USD -0.19
QIAGEN NV €15.14 EUR -0.04
Waters Corp $110.72 USD +0.32
View Industry Companies

Industry Analysis


Industry Average

Valuation ILMN Industry Range
Price/Earnings 100.0x
Price/Sales 13.0x
Price/Book 12.5x
Price/Cash Flow 80.7x
TEV/Sales 11.8x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at